MultiStem: Phase II ongoing

Athersys said an independent safety committee recommended continuation to the high dose of MultiStem in a double-blind, placebo-controlled, U.S. Phase II trial based on a review of safety data. The trial is evaluating single doses of IV MultiStem given 24-36 hours following a stroke in about 140 patients. MultiStem has Orphan Drug designation in the U.S for mucopolysaccharidosis I (MPS-I, Hurler's syndrome) and graft-versus-host disease (GvHD). The product is also in Phase II testing to treat ulcerative colitis (UC) and inflammatory bowel disease (IBD), and Phase I testing to treat acute myocardial infarction (MI). ...